Monthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care - Colorectal Cancer
Emerging Approaches to Personalized Medicine in Colorectal Cancer
Personalizing treatment selection for each patient with localized colon cancer or metastatic colorectal cancer (mCRC) can maximize the benefits while minimizing the harms to give each patient the best survival and quality of life possible. Clinicians must be knowledgeable about new trial results, new systemic therapy options, new biomarkers, and other treatment-selection criteria in order to help patients make the best informed decisions possible.
This educational program is designed to meet the educational needs of physicians, nurses, pharmacists, and other healthcare professionals who manage patients with cancer.
Following this activity, participants should be able to:
- Discuss recent data regarding optimal adjuvant treatment strategies for patients with stage III colon cancer.
- Describe criteria for treatment selection in patients with advanced colorectal cancer.
- Explain the results of recent clinical trials for new and emerging treatment options to inform decision making for patients with advanced colorectal cancer.
Jeffrey Meyerhardt, MD, MPH
Dana-Farber Cancer Institute
Jonathan A. Nowak, MD, PhD
Dana-Farber/Brigham and Women’s Cancer Center
NCCN Medical Education Disclosure Policy
It is the policy of NCCN that every 12 months, all faculty, moderators, activity planners and all internal planning staff participating in NCCN continuing education activities are expected to disclose any financial relationships with a commercial interest as defined by the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support. In addition, all faculty presentations have been reviewed for adherence to the ACCME’s Standards for Commercial Support (the provider develops activities/educational interventions independent of commercial interests [SCS 1, 2 and 6] by experts on the topics).
Per the ACCME Standards for Commercial Support, individuals who do not disclose relevant financial relationships will be disqualified from involvement in the CE activity as a content developer, planner, or presenter. A complete list of individuals’ relationships with external entities is available upon request.
NCCN continuing education considers financial relationships to create a “conflict of interest” when an individual has both a financial relationship with a commercial interest and the opportunity to affect CE content about the products or services of a commercial interest with which he/she and/or a spouse or partner has a financial relationship.
NCCN continuing education considers “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that create a conflict of interest. NCCN does not set a minimal dollar amount for relationships to be significant. Inherent in any amount is the incentive to maintain or increase the value of the relationship.
All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.
Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling.
The faculty listed below discloses no relevant financial relationships:
Jonathan A. Nowak, MD, PhD
The faculty listed below disclose the following relevant financial relationships:
Jeffrey Meyerhardt, MD, MPH
Cota Healthcare: Consulting Fee
Ignyta: Consulting Fee
Taiho Parmaceuticals Co., Ltd.: Other financial benefit
NCCN Staff Disclosures
The NCCN Activity Planning staff listed below discloses no relevant financial relationships:
Melissa Esplen; Mark A. Geisler; Kristina M. Gregory, RN, MSN, OCN; Kristin Kline Hasson; Rose Joyce; Karen Kanefield; Joan S. McClure, MS (employed by NCCN until 8/1/2018); Lisa Perfidio, MS; Shannon Ryan; Sarah Sinclair; Kathy Ann Smith, CHCP
The NCCN Activity Planning staff listed below discloses the following relevant financial relationships:
Donald Harting, ELS, CHCP (employed by NCCN until 12/3/2018)
Laboratory Corporation of America (LabCorp): Equity interest/Stock Options
Katherine Pierce (employed by NCCN until 11/16/2018)
Boston Scientific Corporation: Equity Interest/Stock Options
Pfizer Inc.: Equity Interest/Stock Options
The NCCN Clinical staff listed below discloses no relevant financial relationships:
Lisa Gurski, PhD
In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
NCCN designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
NCCN designates this educational activity for a maximum of 1.0 contact hour.
NCCN designates this knowledge-based continuing education activity for 1.0 contact hour (0.10 CEUs) of continuing education credit. UAN: JA4008196-0000-19-018-L01-P
NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. PAs should only claim credit commensurate with the extent of their participation.
This program has been pre-approved by The Commission for Case Manager Certification to provide continuing education credit to CCM® board certified case managers. The course is approved for 1.0 CE contact hour. Activity Code: I00036835; Approval #: 190001356
- 1.00 AAPA Category 1 CME credit
- 1.00 ACPE contact hours
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ANCC contact hours
- 1.00 CCM clock hours
- 1.00 Participation
This webinar was presented live one time only on Thursday, April 18, 2019, from 1:30 - 2:30 PM Eastern Daylight Time (EDT) (UTC -4).
To complete this activity, users will need:
- A device with an Internet connection and sound playback capability
- One of the two latest versions of Google Chrome, Mozilla Firefox, or Safari
- Internet Explorer is no longer supported
- Adobe Reader or other PDF reader software for certificate viewing/printing